Literature DB >> 21950682

Validity of HMGB1 measurement in epithelial lining fluid in patients with COPD.

Hiroshi Kanazawa1, Yoshihiro Tochino, Kazuhisa Asai, Yukikazu Ichimaru, Tetsuya Watanabe, Kazuto Hirata.   

Abstract

BACKGROUND: It has been known that high-mobility group box 1 (HMGB1) plays an important role in the pathogenesis of various inflammatory disorders in the lung. We attempted to determine the validity of measurement of HMGB1 levels in epithelial lining fluid (ELF) from patients with chronic obstructive pulmonary disease (COPD).
MATERIALS AND METHODS: We measured HMGB1 levels in ELF separately obtained from central or peripheral airways using a bronchoscopic microsampling technique in 14 non-smokers, 13 smokers without COPD and 30 smokers with COPD. We also evaluated whether those levels were correlated with the indexes of pulmonary function and grade of low-attenuation area (LAA) on high-resolution computed tomographic scans.
RESULTS: HMGB1 levels in ELF from central airways did not significantly differ among the three groups. However, HMGB1 levels in peripheral airways were significantly higher in COPD patients than in non-smokers and smokers without COPD. Both the concentrations of interleukin-8 and human polymorphonuclear elastase in peripheral airways were also significantly higher in COPD patients. Moreover, those levels were significantly correlated with HMGB1 level. In addition, HMGB1 level in peripheral airways was closely correlated with the degree of airflow obstruction and grade of LAA in COPD patients.
CONCLUSIONS: HMGB1 levels in peripheral airways were elevated in smokers without COPD, as compared with non-smokers, and those levels were further augmented in COPD patients. Those levels were associated with the severity of COPD. Therefore, HMGB1 in peripheral airways may be a potentially interesting target for new pharmacological treatments in COPD patients.
© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21950682     DOI: 10.1111/j.1365-2362.2011.02598.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  13 in total

Review 1.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

Review 2.  RAGE: a new frontier in chronic airways disease.

Authors:  Maria B Sukkar; Md Ashik Ullah; Wan Jun Gan; Peter A B Wark; Kian Fan Chung; J Margaret Hughes; Carol L Armour; Simon Phipps
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 3.  DAMPs activating innate and adaptive immune responses in COPD.

Authors:  S D Pouwels; I H Heijink; N H T ten Hacken; P Vandenabeele; D V Krysko; M C Nawijn; A J M van Oosterhout
Journal:  Mucosal Immunol       Date:  2013-10-23       Impact factor: 7.313

4.  Respiratory Syncytial Virus Infection Triggers Epithelial HMGB1 Release as a Damage-Associated Molecular Pattern Promoting a Monocytic Inflammatory Response.

Authors:  Yashoda M Hosakote; Allan R Brasier; Antonella Casola; Roberto P Garofalo; Alexander Kurosky
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

5.  Ulinastatin protects the lungs of COPD rats through the HMGB1/TLR4 signaling pathway.

Authors:  Wei Liu; Zhiguang Liu; Weidong Zhang; Shaoxi Cai
Journal:  Oncol Lett       Date:  2018-07-11       Impact factor: 2.967

Review 6.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 7.  Mitochondrial Regulation of Inflammasome Activation in Chronic Obstructive Pulmonary Disease.

Authors:  Chang Min Yoon; Milang Nam; Yeon-Mok Oh; Charles S Dela Cruz; Min-Jong Kang
Journal:  J Innate Immun       Date:  2015-11-05       Impact factor: 7.349

Review 8.  Inflammation and immune response in COPD: where do we stand?

Authors:  Nikoletta Rovina; Antonia Koutsoukou; Nikolaos G Koulouris
Journal:  Mediators Inflamm       Date:  2013-07-15       Impact factor: 4.711

9.  High-mobility group box 1 impairs airway epithelial barrier function through the activation of the RAGE/ERK pathway.

Authors:  Wufeng Huang; Haijin Zhao; Hangming Dong; Yue Wu; Lihong Yao; Fei Zou; Shaoxi Cai
Journal:  Int J Mol Med       Date:  2016-03-24       Impact factor: 4.101

Review 10.  Association between HMGB1 and COPD: A Systematic Review.

Authors:  Sebastiano Gangemi; Marco Casciaro; Giovanni Trapani; Sebastiano Quartuccio; Michele Navarra; Giovanni Pioggia; Egidio Imbalzano
Journal:  Mediators Inflamm       Date:  2015-12-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.